JP7021083B2 - 免疫応答を誘導するための方法および手段 - Google Patents

免疫応答を誘導するための方法および手段 Download PDF

Info

Publication number
JP7021083B2
JP7021083B2 JP2018520486A JP2018520486A JP7021083B2 JP 7021083 B2 JP7021083 B2 JP 7021083B2 JP 2018520486 A JP2018520486 A JP 2018520486A JP 2018520486 A JP2018520486 A JP 2018520486A JP 7021083 B2 JP7021083 B2 JP 7021083B2
Authority
JP
Japan
Prior art keywords
rna
composition
protamine
particles
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018520486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532742A5 (enExample
JP2018532742A (ja
Inventor
スティーヴ・パスコロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of JP2018532742A publication Critical patent/JP2018532742A/ja
Publication of JP2018532742A5 publication Critical patent/JP2018532742A5/ja
Priority to JP2022015705A priority Critical patent/JP2022062175A/ja
Application granted granted Critical
Publication of JP7021083B2 publication Critical patent/JP7021083B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001141—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018520486A 2015-10-21 2016-10-20 免疫応答を誘導するための方法および手段 Expired - Fee Related JP7021083B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022015705A JP2022062175A (ja) 2015-10-21 2022-02-03 免疫応答を誘導するための方法および手段

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/074389 2015-10-21
PCT/EP2015/074389 WO2017067593A1 (en) 2015-10-21 2015-10-21 Methods and means for inducing an immune response
PCT/EP2016/075156 WO2017068016A1 (en) 2015-10-21 2016-10-20 Methods and means for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022015705A Division JP2022062175A (ja) 2015-10-21 2022-02-03 免疫応答を誘導するための方法および手段

Publications (3)

Publication Number Publication Date
JP2018532742A JP2018532742A (ja) 2018-11-08
JP2018532742A5 JP2018532742A5 (enExample) 2019-08-15
JP7021083B2 true JP7021083B2 (ja) 2022-02-16

Family

ID=54347522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520486A Expired - Fee Related JP7021083B2 (ja) 2015-10-21 2016-10-20 免疫応答を誘導するための方法および手段
JP2022015705A Pending JP2022062175A (ja) 2015-10-21 2022-02-03 免疫応答を誘導するための方法および手段

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022015705A Pending JP2022062175A (ja) 2015-10-21 2022-02-03 免疫応答を誘導するための方法および手段

Country Status (6)

Country Link
US (2) US20180318436A1 (enExample)
EP (1) EP3365024A1 (enExample)
JP (2) JP7021083B2 (enExample)
AU (1) AU2016341181A1 (enExample)
CA (1) CA2996467A1 (enExample)
WO (2) WO2017067593A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
SG11202101732WA (en) 2018-10-01 2021-03-30 Univ Mainz Johannes Gutenberg Rna particles comprising polysarcosine
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
JP2022545786A (ja) * 2019-09-01 2022-10-31 アカデミア シニカ ナノコンポジット粒子及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200639B1 (en) * 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
WO2009046739A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOURQUIN, C. et al.，Cancer Res，2011年，Vol. 71，pp. 5123-33

Also Published As

Publication number Publication date
WO2017067593A1 (en) 2017-04-27
JP2022062175A (ja) 2022-04-19
US20180318436A1 (en) 2018-11-08
US20220347308A1 (en) 2022-11-03
WO2017068016A1 (en) 2017-04-27
CA2996467A1 (en) 2017-04-27
EP3365024A1 (en) 2018-08-29
AU2016341181A1 (en) 2018-04-12
JP2018532742A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
US9636414B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
KR102264820B1 (ko) 지질과 리포좀의 안정된 제제
JP2022062175A (ja) 免疫応答を誘導するための方法および手段
EP2772251B1 (en) Protamine/RNA nanoparticles for immunostimulation
US10626400B2 (en) Stabilised formulations of RNA
US20240335511A1 (en) Therapeutic rna for treating cancer
US20240041999A1 (en) Therapeutic RNA for Treating Cancer
US10172960B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
EP3145550B1 (en) Particles comprising protamine and rna in combination with endosome destabilizing agents
HK1242215A1 (en) Stable formulations of lipids and liposomes
HK1240829A1 (en) Stable formulations of lipids and liposomes
HK1240829B (en) Stable formulations of lipids and liposomes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220203

R150 Certificate of patent or registration of utility model

Ref document number: 7021083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees